Investigational new drugs for allergic rhinitis

References

• Casale TB, Stokes JR. Future forms of immunotherapy. J Allergy Clin Immunol. 2011;127:815.
   PubMed Web of Science ®Google Scholar
• Bousquet J, Khaltaev N, Cruz AA, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 2008;63:8–160.
   PubMed Web of Science ®Google Scholar
• Noon L. Prophylactic inoculation against hay fever. Lancet. 1911;1:1572.
   Google Scholar
• Freeman J. Further observations on the treatment of hay fever by hypodermic inoculations of pollen vaccine. Lancet. 1911;2:814–817.
   Google Scholar
• Casale TB, Stokes JR. Immunotherapy: what lies beyond. J Allergy Clin Immunol. 2014;133:612–619.
   PubMed Web of Science ®Google Scholar
• Cox L, Jacobson L. Comparison of allergen immunotherapy practice patterns in the United States and Europe. Ann Allergy Asthma Immunol. 2009;103:451-459; quiz 459-461:495.
   Web of Science ®Google Scholar
• Focke M, Swoboda I, Marth K, et al. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity. Clin Exp Allergy. 2010;40:385–397.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;24(1):CD001936.
   PubMed Web of Science ®Google Scholar
• Adkis M, Adkis CA. Mechanisms of allergen-specific immunotherapy: multiple suppressor factors in immune tolerance in allergens. J Allergy Clin Immunol. 2014;133:621–631.
   PubMed Web of Science ®Google Scholar
• Burks AW, Calderon MA, Casale TB, et al. Update on allergy immunotherapy: american Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131:1288–1296.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Casale TB. Allergic rhinitis and asthma: celebrating 100 years of immunotherapy. Curr Opin Immunol. 2011;23(6):808–813.
   PubMed Web of Science ®Google Scholar
• Segal M, Stokes JR, Casale TB. Anti-Immunoglobulin E therapy. World Allergy Organ J. 2008;1:174–183.
   PubMedGoogle Scholar
• Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol. 2006;117:134–140.
   PubMed Web of Science ®Google Scholar
• Kopp MV, Hamelmann E, Bendiks M, et al. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy. Pediatr Allergy Immunol. 2013;24:427–433.
   PubMed Web of Science ®Google Scholar
• Massanari M, Nelson H, Casale T, et al. Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. J Allergy Clin Immunol. 2010;125:383–389.
   PubMed Web of Science ®Google Scholar
• Li JT, Bernstein DI, Calderon MA, et al. Sublingual grass and ragweed immunotherapy: clinical considerations – a PRACTALL consensus report. J Allergy Clin Immunol. 2016;137:369–376.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Esch RE, Couroux P, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014;133:751–758.
   PubMed Web of Science ®Google Scholar
• Durham SR, Yang WH, Pedersen MR, et al. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006;117:802–809.
   PubMed Web of Science ®Google Scholar
• Didier A, Malling HJ, Worm M, et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol. 2007;120:1338–1345.
   PubMed Web of Science ®Google Scholar
• Lee S, Nolte H, Benninger MS. Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis. Am J Rhinol Allergy. 2015;29:106–114.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Bousquet J, Casale T, et al. Sub-lingual immunotherapy: world allergy organization position paper. World Allergy Org J. 2009;2:233–281.
   PubMedGoogle Scholar
• Moingeon P, Mascarell L. Induction of tolerance via the sublingual route: mechanisms and applications. Clin Dev Immunol. 2012;2012:623474.
   PubMedGoogle Scholar
• Bergmann KC, Demoly P, Worm M, et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol. 2014;133:1608–1614.e6.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Deckelmann R, De Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014;134:568–575.e7.
   PubMed Web of Science ®Google Scholar
• Nolte H, Maloney J, Nelson HS, et al. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber. J Allergy Clin Immunol. 2015;135:1494–1501.e6.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Canonica GW, Becker V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015;114:134–140.e1.
   PubMed Web of Science ®Google Scholar
• Demoly P, Calderon MA, Casale TB, et al. The value of pre- and co-seasonal sublingual immunotherapy in pollen-induced allergic rhinoconjunctivitis. Clin Trans Allergy. 2015;5(18):eCollection 2015.
   Google Scholar
• RAGWITEK (Short Ragweed Pollen Allergen Extract) Tablet for Sublingual Use [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a Subsidiary of Merck & Co., Inc.; June 2014. cited 2016 Aug 4. Available from: https://www.ragwitek.com/
   Google Scholar
• ORALAIR (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract) Tablet for Sublingual Use [package insert]. Antony, France: Stallergenes S.A.; Oct 2014; cited 2016 Aug 4. Available from: http://www.oralair.com/
   Google Scholar
• GRASTEK (Timothy Grass Pollen Extract) Tablet for Sublingual Use [package insert]. Whitehouse Station, NJ: Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.; June 2014; cited 2016 Aug 4. Available from: https://www.grastek.com/
   Google Scholar
• Devillier P, Dreyfus JF, Demoly CM, et al. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC Med. 2014;12:71.
   PubMed Web of Science ®Google Scholar
• Strunk RC, Sternberg AL, Szefler SJ, et al. Long-term budesonide or nedocromil treatment, once discontinued does not alter the course of mild to moderate asthma in children and adolescents. J Pediatr. 2009;154:682–687.
   PubMed Web of Science ®Google Scholar
• Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012;129:717–725.e5.
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010;126:969–975.
   PubMed Web of Science ®Google Scholar
• Di Bona D, Plaia A, Scafidi V, et al. Efficacy of sublingual immunotherapy with grass allergens for seasonal allergic rhinitis: a systematic review and meta-analysis. J Allergy Clin Immunol. 2010;126:558–566.
   PubMed Web of Science ®Google Scholar
• Radulovic S, Wilson D, Calderon M, et al. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011;66:740–752.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for allergic conjunctivitis: cochrane systematic review and meta-analysis. Clin Exp Allergy. 2011;41:1263–1272.
   PubMed Web of Science ®Google Scholar
• Lin SY, Erekosima N, Kim JM, et al. Sublingual immunotherapy for the treatment of allergic rhinoconjunctivitis and asthma: a systemic review [published erratum in: JAMA 2013;310:647. Jama. 2013;309:1278–1288.
   PubMed Web of Science ®Google Scholar
• Dretzke J, Meadows A, Novielli N, et al. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: A systematic review and indirect comparison. J Allergy Clin Immunol. 2013;131:1361–1366.
   PubMed Web of Science ®Google Scholar
• Durham SR, Penagos M. Sublingual or subcutaneous immunotherapy for allergic rhinitis. J Allergy Clin Immunol. 2016;137:339–349.
   PubMed Web of Science ®Google Scholar
• Maloney J, Bernstein DI, Nelson H, et al. Efficacy and safety of grass sublingual immunotherapy tablet. MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol. 2014;112:146–153.e2.
   PubMed Web of Science ®Google Scholar
• Nolte H, Hébert J, Berman G, et al. Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol. 2013;110:450–456.e4.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Maloney J, Bernstein DI, et al. Randomized controlled trial of a ragweed allergy immunotherapy tablet efficacy and safety in North American and European adults. J Allergy Clin Immunol. 2013;131:1342–1349.
   PubMed Web of Science ®Google Scholar
• Calderon MA, Casale TB, Nelson HS, et al. An evidence-based analysis of house dust mite allergen immunotherapy: A call for more rigorous clinical studies. J Allergy Clin Immunol. 2013;132:1322–1336.
   PubMed Web of Science ®Google Scholar
• Klimek L, Mosbech H, Zieglmayer P, et al. SQ house dust mite (HDM) SLIT-tablet provides clinical improvement in HDM-induced allergic rhinitis. Expert Rev Clin Immunol. 2016;12(4):369–377.
   PubMed Web of Science ®Google Scholar
• Canonica GW, Virchow JC, Zieglmayer P, et al. Efficacy and safety of SQ house dust mite (HDM) SLIT-tablet treatment of HDM allergic asthma. Expert Rev Clin Immunol. 2016 Aug;12(8):805–815.
   PubMed Web of Science ®Google Scholar
• Mosbech H, Canonica GW, Backer V, et al. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms. Ann Allergy Asthma Immunol. 2015;114:134–140.
   PubMed Web of Science ®Google Scholar
• Demoly P, Emminger W, Rehm D, et al. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2016 Feb;137(2):444–451.e8.
   PubMed Web of Science ®Google Scholar
• Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: a randomized clinical trial. Jama. 2016;315(16):1715–1725.
   PubMed Web of Science ®Google Scholar
• Nolte H, Bernstein DI, Nelson HS, et al. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2016 Aug 10; pii: S0091-6749(16)30783-7. [Epub ahead of print] PubMed PMID: 27521719. DOI: 10.1016/j.jaci.2016.06.044
   Web of Science ®Google Scholar
• Karakoc-Aydiner E, Eifan AO, Baris S, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite-allergic children with asthma/rhinitis: A 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol. 2015;25(5):334–342.
   PubMed Web of Science ®Google Scholar
• Durham SR, Creticos PS, Nelson HS, et al. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: pooled analyses. J Allergy Clin Immunol. 2016;pii: S0091-6749(16)30614-5. DOI:10.1016/j.jaci.2016.04.061
   Web of Science ®Google Scholar
• Maloney J, Berman G, Gagnon R, et al. Sequential treatment initiation with timothy grass and ragweed sublingual immunotherapy tablets followed by simultaneous treatment is well tolerated. J Allergy Clin Immunol Pract. 2016;4(2):301–309.e2.
   PubMed Web of Science ®Google Scholar
• Marogna M, Spadolini I, Massolo A, et al. Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Ann Allergy Asthma Immunol. 2007;98(3):274–280.
   PubMed Web of Science ®Google Scholar
• Moreno-Ancillo A, Moreno C, Ojeda P, et al. Efficacy and quality of life with once-daily sublingual immunotherapy with grasses plus olive pollen extract without updosing. J Investig Allergol Clin Immunol. 2007;17(6):399–405.
   PubMed Web of Science ®Google Scholar
• Amar SM, Harbeck RJ, Sills M, et al. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol. 2009;124(1):150–156.
   PubMed Web of Science ®Google Scholar
• Di Bona DD, Plaia A, Leto-Barone MS, et al. Efficacy of grass pollen allergen sublingual immunotherapy tablets for seasonal allergic rhinoconjunctivitis. JAMA Int Med. 2015;175(8):1301–1309.
   PubMed Web of Science ®Google Scholar
• Cox LS, Linneman DL, Nolte H, et al. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol. 2006;117:1021–1035.
   PubMed Web of Science ®Google Scholar
• Antico A, Fante R. Esophageal hypereosinophilia induced by grass sublingual immunotherapy. J Allergy Clin Immunol. 2014;133(5):1482–1484.
   PubMed Web of Science ®Google Scholar
• Miehlke S, Alpan O, Shröder S, et al. Induction of eosinophilic esophagitis by sublingual pollen immunotherapy. Case Rep Gastroenterol. 2013;7(3):363–368.
   PubMedGoogle Scholar
• Normansell R, Kew KM, Bridgman AL. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2015;28(8):CD011293.
   Google Scholar
• Nelson HS, Makatsori M, Calderon MA. Subcutaneous immunotherapy and sublingual immunotherapy: comparative efficacy, current and potential indications, and warnings – United States versus Europe. Immunol Allergy Clin North Am. 2016;36:13–24.
   PubMed Web of Science ®Google Scholar
• Senna G, Lombardi C, Canonica GW, et al. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers’ viewpoint. J Allergy Clin Immunol. 2010;126(3):668–669.
   PubMed Web of Science ®Google Scholar
• Blamoutier P, Blamoutier J, Guibert L. Treatment of pollinosis with pollen extracts by the method of cutaneous quadrille ruling [in French]. Presse Med. 1959;67:2299–2301.
   PubMed Web of Science ®Google Scholar
• Senti G, Graf N, Haug S, et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J Allergy Clin Immunol. 2009;124:997–1002.
   PubMed Web of Science ®Google Scholar
• Senti G, Von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind placebo-controlled dose escalation study. J Allergy Clin Immunol. 2012;129:128–135.
   PubMed Web of Science ®Google Scholar
• Werfel T. Epicutaneous allergen administration: A novel approach for allergen-specific immunotherapy? J Allergy Clin Immunol. 2009;124:1003–1004.
   PubMed Web of Science ®Google Scholar
• Turjanmaa K, Darsow U, Niggemann B, et al. EAACI/GA2-LEN position paper: present status of the atopy patch test. Allergy. 2006;61:1377–1384.
   PubMed Web of Science ®Google Scholar
• Senti G, Johansen P, Erdmann I, et al. Intralymphatic immunotherapy. Curr Opin Allergy Clin Immunol. 2009;9:537–543.
   PubMed Web of Science ®Google Scholar
• Martinez-Gomez JM, Johansen P, Erdmann I, et al. Intralymphatic injections as a new administration of route for allergen-specific immunotherapy. Int Arch Allergy Immunol. 2009;150:59–65.
   PubMed Web of Science ®Google Scholar
• Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci USA. 2008;105:17908–17912.
   PubMed Web of Science ®Google Scholar
• Senti G, Crameri R, Kuster D, et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012;129:1290–1296.
   PubMed Web of Science ®Google Scholar
• Kundig TM. Immunotherapy concepts under investigation. Allergy. 2011;66:60–62.
   PubMed Web of Science ®Google Scholar
• Hylander T, Latif L, Petersson-Westin U, et al. Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis. J Allergy Clin Immunol. 2013;131:412–420.
   PubMed Web of Science ®Google Scholar
• Witten M, Malling HJ, Blom L, et al. Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy? J Allergy Clin Immunol. 2013;132:1248–1252.e5.
   PubMed Web of Science ®Google Scholar
• Marcucci F, Sensi LG, Caffarelli C, et al. Low-dose local nasal immunotherapy in children with perennial allergic rhinitis due to Dermatophagoides. Allergy. 2002;57:23–28.
   PubMed Web of Science ®Google Scholar
• Tsai JJ, Liao EC, Tsai FH, et al. The effect of local nasal immunotherapy in allergic rhinitis: using strips of the allergen Dermatophagoides pteronyssinus. J Asthma. 2009;46:165–170.
   PubMed Web of Science ®Google Scholar
• Reisacher W, Rudner S, Kotik V. Oral mucosal immunotherapy using a toothpaste delivery system for the treatment of allergic rhinitis. Int J Pharm Compd. 2014;18(4):287–290.
   Google Scholar
• Van Rijswijk JB, Blom HM, Fokkens WJ. Idiopathic rhinitis, the ongoing quest. Allergy. 2005;60(12):1471–1481.
   PubMed Web of Science ®Google Scholar
• Bernstein JA, Davis BP, Picard JK, et al. A randomized, double-blind, parallel trial comparing capsaicin nasal spray with placebo in subjects with a significant component of nonallergic rhinitis. Ann Allergy Asthma Immunol. 2011;107:171.
   PubMed Web of Science ®Google Scholar
• Ridolo E, Montagni M, Caminati M, et al. Emerging drugs for allergic conjunctivitis. Expert Opin Emerg Drugs. 2014;19(2):291–302.
   PubMed Web of Science ®Google Scholar
• Barchuk WT, Salapatek AM, Ge T, et al. A proof-of-concept study of the effect of the novel H3-receptor antagonist in allergen-induced nasal congestion. J Allergy Clin Immunol. 2013;132(4):838-846.e1-e6.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Romero FA Jr, Allan RJ, et al. The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms. J Allergy Clin Immunol. 2012;129(2):409-12.e1-2.
   PubMed Web of Science ®Google Scholar
• North ML, Walker TJ, Steacy LM, et al. Add-on histamine receptor-3 antagonist for allergic rhinitis: a double-blind randomized crossover trial using the environmental exposure unit. Allergy Asthma Clin Immunol. 2014;10(1):33.
   PubMed Web of Science ®Google Scholar
• Daley-Yates P, Ambery C, Sweeney L, et al. The efficacy and tolerability of two novel H(1)/H(3) receptor antagonists in seasonal allergic rhinitis. Int Arch Allergy Immunol. 2012;158(1):84–98.
   PubMed Web of Science ®Google Scholar
• Osguthorpe JD. Pathophysiology of and potential new therapies for allergic rhinitis. Int Forum Allergy Rhinol. 2013;3(5):384–392.
   PubMed Web of Science ®Google Scholar
• Raap U, Braunstahl GJ. The role of neurotrophins in the pathophysiology of allergic rhinitis. Curr Opin Allergy Clin Immunol. 2010;10:8–13.
   PubMed Web of Science ®Google Scholar
• Lazewska D, Kiec-Kononowicz K. Azines as histamine H4 receptor antagonists. Front Biosci (Schol Ed). 2012;4:967–987.
   PubMedGoogle Scholar
• Valenta R, Niederberoer R. Recombinant allergens for immunotherapy. J Allergy Clin Immunol. 2007;119:826–830.
   PubMed Web of Science ®Google Scholar
• Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761–771.
   PubMed Web of Science ®Google Scholar
• Niederberger V, Horak F, Vrtaa S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acaad Sci USA. 2004;101(Suppl 2):14677–14682.
   PubMed Web of Science ®Google Scholar
• Valenta R, Ferreira F. Focke-Tejkl, et al. From allergen genes to allergen vaccines. Annu Rev Immunol. 2010;28:211–241.
   PubMed Web of Science ®Google Scholar
• Gafvelin G, Thunberg S, Kronqvist M, et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol. 2005;138:59–66.
   PubMed Web of Science ®Google Scholar
• Reisenger J, Horak F, Pauli G, et al. Allergen specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol. 2005;116:347–354.
   PubMed Web of Science ®Google Scholar
• Niederberger V, Reisenger S, Valent P, et al. Vaccination with genetically modified birch pollen allergens: immune and clinical effects on oral allergy syndrome. J Allergy Clin Immunol. 2007;119:1013–1016.
   PubMed Web of Science ®Google Scholar
• Jutel M, Jäger L, Suck R, et al. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol. 2005;116:608–613.
   PubMed Web of Science ®Google Scholar
• Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2009;122:951–960.
   Web of Science ®Google Scholar
• Larché M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol. 2007;119:906–909.
   PubMed Web of Science ®Google Scholar
• Briner TJ, Kuo MC, Keating KM, et al. Peripheral T-cell tolerance. induced in naive and primed mice by subcutaneous injection of peptides from the major cat allergen Fel d I. Proc Natl Acad Sci USA. 1993;90:7608–7612.
   PubMed Web of Science ®Google Scholar
• Wallner BP, Gefter ML. Immunotherapy with T-cell-reactive peptides derived from allergens. Allergy. 1994;49:302–308.
   PubMed Web of Science ®Google Scholar
• Patel D, Couroux P, Hickey P, et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study. J Allergy Clin Immunol. 2013;131:103–109.
   PubMed Web of Science ®Google Scholar
• Couroux P, Patel D, Armstrong K, et al. Fel d 1-derived synthetic peptide immune-regulatory epitopes show a long-term treatment effect in cat allergic subjects. Clin Exp Allergy. 2015;45(5):974–981.
   PubMed Web of Science ®Google Scholar
• Racila DM, Kline JN. Perspectives in asthma: molecular use of microbial products in asthma prevention and treatment. J Allergy Clin Immunol. 2005;116(6):1202–1205.
   PubMed Web of Science ®Google Scholar
• Tulic MK, Fiset PO, Manoukian JJ, et al. Role of toll-like receptor 4 in protection by bacterial lipopolysaccharide in the nasal mucosa of atopic children but not adults. Lancet. 2004;363(9422):1689–1697.
   PubMed Web of Science ®Google Scholar
• Gawchik SM, Saccar CL. Pollinex Quattro Tree: allergy vaccine. Expert Opin Biol Ther. 2009;9(3):377–382.
   PubMed Web of Science ®Google Scholar
• Baldrick P, Richardson D, Wheeler AW. Safety evaluation of a glutaraldehyde modified tyrosine adsorbed housedust mite extract containing monophosphoryl lipid A (MPL) adjuvant: a new allergy vaccine for dust mite allergy. Vaccine. 2001;20:737–743.
   PubMed Web of Science ®Google Scholar
• Rosewich M, Lee D, Zielen S. Pollinex Quattro: an innovative four injections immunotherapy in allergic rhinitis. Hum Vaccin Immunother. 2013;9(7):1523–1531.
   PubMed Web of Science ®Google Scholar
• Aryan Z, Rezaei N. Toll-like receptors as targets for allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2015;15(6):568–574.
   PubMed Web of Science ®Google Scholar
• Drachenberg KJ, Wheeler AW, Stuebner P, et al. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001;56(6):498–505.
   PubMed Web of Science ®Google Scholar
• Mccormack PL, Wagstaff AJ. Ultra-short-course seasonal allergy vaccine (Pollinex Quattro). Drugs. 2006;66(7):931–938.
   PubMed Web of Science ®Google Scholar
• Zielen S, Metz D, Sommer E, et al. Short-term immunotherapy with allergoids and the adjuvant monophosphoryl lipid a. Results from a 3-year postmarketing surveillance study. Allergologie. 2007;30:S1–9.
   Web of Science ®Google Scholar
• Rosewich M, Schulze J. Fischer von weikersthal-drachenberg KJ, Zielen S. Ultra-short course immunotherapy in children and adolescents during a 3-yrs post-marketing surveillance study. Pediatr Allergy Immunol. 2010;21(1 Pt 2):e185–9.
   PubMed Web of Science ®Google Scholar
• Casale TB, Kessler J, Romero FA. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis. Ann Allergy Asthma Immunol. 2006;97(4):454–456.
   PubMed Web of Science ®Google Scholar
• Pfaar O, Barth C, Jaschke C, et al. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a phase I/IIa study. Int Arch Allergy Immunol. 2011;154(4):336–344.
   PubMed Web of Science ®Google Scholar
• Nelson HS. Allergen immunotherapy now and in the future. Allergy Asthma Proc. 2016;37(4):268–272.
   PubMed Web of Science ®Google Scholar
• Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol. 2000;106(1 Pt 1):124–134.
   PubMed Web of Science ®Google Scholar
• Higgins D, Rodriguez R, Milley R, et al. Modulation of immunogenicity and allergenicity by controlling the number of immunostimulatory oligonucleotides linked to Amb a 1. J Allergy Clin Immunol. 2006;118(2):504–510.
   PubMed Web of Science ®Google Scholar
• Tulic MK, Fiset PO, Christodoulopoulos P, et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response. J Allergy Clin Immunol. 2004;113(2):235–241.
   PubMed Web of Science ®Google Scholar
• Creticos PS, Schroeder JT, Hamilton RG, et al. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006;355(14):1445–1455.
   PubMed Web of Science ®Google Scholar
• Stokes JR, Casale TB. Novel Approaches of Immunotherapy. Curr Treat Options Allergy. 2014;1(1):58–67.
   Google Scholar
• Senti G, Johansen P, Haug S, et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial. Clin Exp Allergy. 2009;39(4):562–570.
   PubMed Web of Science ®Google Scholar
• Klimek L, Willers J, Hammann-Haenni A, et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a phase IIb study. Clin Exp Allergy. 2011;41(9):1305–1312.
   PubMed Web of Science ®Google Scholar
• Beeh KM, Kanniess F, Wagner F, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol. 2013;131(3):866–874.
   PubMed Web of Science ®Google Scholar
• Casale TB, Cole J, Beck E, et al. CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study. Allergy. 2015;70(9):1160–1168.
   PubMed Web of Science ®Google Scholar
• Greiff L, Cervin A, Ahlström-Emanuelsson C, et al. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis. Respir Res. 2012;13:53.
   PubMed Web of Science ®Google Scholar
• Delaney S, Biffen M, Maltby J, et al. Tolerability in man following inhalation dosing of the selective TLR7 agonist, AZD8848. BMJ Open Respir Res. 2016;3(1):e000113.
   PubMed Web of Science ®Google Scholar
• Horak F. VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2011;20(7):981–986.
   PubMed Web of Science ®Google Scholar
• Henmar H, Lund G, Lund L, et al. Allergenicity, immunogenicity and dose-relationship of three intact allergen vaccines and four allergoid vaccines for subcutaneous grass pollen immunotherapy. Clin Exp Immunol. 2008;153(3):316–323.
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Kettner J, Doemer C, et al. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy. 2005;60(6):801–807.
   PubMed Web of Science ®Google Scholar
• Dominicus R. 3-years’ long-term effect of subcutaneous immunotherapy (SCIT) with a high-dose hypoallergenic 6-grass pollen preparation in adults. Eur Ann Allergy Clin Immunol. 2012;44(3):135–140.
   PubMedGoogle Scholar
• Pfaar O, Robinson DS, Sager A, et al. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy. 2010;65(12):1614–1621.
   PubMed Web of Science ®Google Scholar
• Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol. 2010;126(5):942–949.
   PubMed Web of Science ®Google Scholar
• Nieto García A, Nevot Falcó S, Carrillo Díaz T, et al. Safety of cluster specific immunotherapy with a modified high-dose house dust mite extract. Eur Ann Allergy Clin Immunol. 2013;45(3):78–83.
   PubMedGoogle Scholar
• Castillo J, Dimov V. Investigational drugs for the treatment of allergic rhinitis. Expert Opin Investig Drugs. 2014;23(6):823–836.
   PubMed Web of Science ®Google Scholar